Here you will find the Publications from 2010 onwards.
EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis. Breast Cancer Res 26(1): 87 (2024) (20 pp)
Chronic stimulation desensitizes β2-adrenergic receptor responses in natural killer cells. Eur J Immunol 54 (12): e2451299 (2024)
Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth. J Exp Clin Cancer Res 42 (1): 25 (2023) (18 pp)